VitaNova Life Sciences Corp
vitanovalifesciences.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Despite revenue tripling to $321,576 from $103,899 year-over-year, VitaNova's gross margin collapsed from ~66% to ~9.5% as cost of revenue outpaced sales growth, driving net loss to nearly triple to $(123,101) from $(46,301). Total assets and shareholders' equity declined quarter-over-quarter, and the company continues to report ineffective disclosure controls with unremediated material weaknesses.
Red Flags Detected (6)
Gross margin compression from ~66% to ~9.5% despite revenue growth, indicating severe cost/pricing pressure
Net loss nearly tripled year-over-year ($123,101 vs $46,301)
Disclosure controls and procedures deemed not effective as of July 31, 2026
3 more red flags detected
Key Takeaways
Revenue growth is being offset by even faster cost growth, resulting in deteriorating unit economics
Company remains small-cap with thin equity base (~$1.9M) and persistent internal control deficiencies
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.